UTHR Q1 2017 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q1 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$371M+0.4% YoY

Gross Profit

$356M96.1% margin

Operating Income

$264M71.1% margin

Net Income

$179M48.2% margin

EPS (Diluted)

$3.89

QoQ Revenue Growth

-9.4%

Cash Flow

Operating Cash Flow

$231M

Free Cash Flow

$215M

Stock-Based Comp.

-$19M

Balance Sheet

Total Assets

$2.6B

Total Liabilities

$485M

Stockholders' Equity

$2.1B

Cash & Equivalents

$1.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$371M	$369M	+0.4%
Gross Profit	$356M	$368M	-3.3%
Operating Income	$264M	$364M	-27.5%
Net Income	$179M	$236M	-24.2%

Revenue Segments

Remodulin

$146M39%

Tyvaso

$87M24%

Adcirca

$80M22%

Orenitram

$39M11%

Unituxin

$18M5%